Brain Structural and Amyloid Correlates of Recovery From Semantic Interference in Cognitively Normal Individuals With or Without Family History of Late-Onset Alzheimer’s Disease (2024)

Information & Authors

Information

Published In

The Journal of Neuropsychiatry and Clinical Neurosciences

Volume 31 • Number 1 • Winter 2019

Pages: 25 - 36

PubMed: 30305005

History

Received: 18 December 2017

Revision received: 14 May 2018

Revision received: 17 May 2018

Accepted: 18 May 2018

Published online: 11 October 2018

Published in print: Winter 2019

Keywords

Alzheimer’s Disease
Cognitive Disorders
Imaging Techniques

Authors

Affiliations

Carolina Abulafia, B.A.

From the Fleni Foundation, Buenos Aires (CA, BDA, SMS, MNC, LJC, SV, GS, SMG, MFV); the Institute for Biomedical Research, Pontifical Catholic University of Argentina, Buenos Aires (CA, DEV); the National Scientific and Technical Research Council, Buenos Aires (CA, SMS, DEV, MNC, LJD, SMG, MFV); the Department of Psychiatry and Mental Health, University of Buenos Aires School of Medicine (MNC, LJD, SMG); the Department of Physics, University of Buenos Aires (SMS, MFV); and the Department of Psychiatry and Behavioral Sciences and Center on Aging, Miller School of Medicine, University of Miami (DL, RC, CBN).

View all articles by this author

David Loewenstein, Ph.D.

View all articles by this author

Notes

Send correspondence to Dr. Guinjoan; e-mail: [emailprotected]

Author Contributions

Drs. Guinjoan and Villarreal contributed equally to this study.

Competing Interests

Ms. Abulafia and Ms. Sánchez are doctoral fellows at the National Scientific and Technical Research Council. Dr. Duarte-Abritta is a doctoral fellow at Agencia, Argentina. Dr. Drucaroff is a postdoctoral student at the National Scientific and Technical Research Council, Argentina. Dr. Nemeroff has received research grant support from NIH and Stanley Medical Research Institute; he has served as a consultant for Bracket, Gerson Lehrman Group Healthcare and Biomedical Council, Fortress Biotech, Janssen Research and Development LLC, Intra-Cellular Therapies, Magstim, Navitor Pharmaceuticals, Prismic Pharmaceuticals, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Taisho Pharmaceutical, TC MSO, Takeda, Total Pain Solutions, and Xhale; he is a shareholder with Abbvie, Antares, BI Gen Holdings, Celgene, Network Life Sciences, OPKO Health, Seattle Genetics, and Xhale; he has served on the scientific advisory boards of the American Foundation for Suicide Prevention, the Anxiety Disorders Association of America, Bracket, the Brain and Behavior Research Foundation, the Laureate Institute for Brain Research, RiverMend Health LLC, Skyland Trail, and Xhale; he has served on the board of directors for The American Foundation for Suicide Prevention, the Anxiety Disorders Association of America, and Gratitude America; he has received royalties, income, or equity from American Psychiatric Association Publishing, Bracket, CME Outfitters, Takeda, and Xhale; and he holds patents for a method and devices for transdermal delivery of lithium (U.S. patent number 6,375,990B1) and a method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (U.S. patent number 7,148,027B2). All other authors report no financial relationships with commercial interests.

Funding Information

Agencia de Promoción, FONCYT, Ministerio de Ciencia y Tecnología, Argentina: PICT-2014-0633

Supported by a grant from Agencia de Promoción, FONCYT (National Found for the Science and Technology), MINCYT (Ministry of Science, Technology, and Productive Development), Argentina (grant PICT-2014-0633).